Recent news coverage includes general market and sector updates but lacks company-specific developments. No material changes in risk factors were reported in the latest quarterly filing.

• Cassava Sciences reported no material changes in risk factors from its 2025 Annual Report in its 2026 Q1 filing [S2].
• The company continues to focus on simufilam development for TSC-related epilepsy with no new product launches or discontinuations since mid-2025 [S1][S2].
• Recent news articles primarily cover broader market and sector topics without direct reference to Cassava Sciences [N1][N2][N3][N4][N5][N6][N7][N8].

The company's focus on a novel target, filamin A, for CNS disorders including TSC-related epilepsy, supported by preclinical evidence, positions it to potentially address unmet medical needs. Outsourcing manufacturing to experienced contract organizations like Evonik may allow efficient resource allocation. Continued clinical progress and validation of simufilam's efficacy and safety could enhance its development prospects.

Risks include the inherent uncertainties of drug development, including regulatory approval challenges and clinical trial outcomes. Dependence on third-party manufacturers introduces supply chain and compliance risks. Competition from approved therapies and other drug candidates with greater resources and market presence may limit commercial opportunities. Financial losses and ongoing R&D expenses highlight the need for sustained funding and operational execution.

Cassava Sciences' moat is based on its proprietary scientific approach targeting filamin A, a novel mechanism for treating TSC-related epilepsy. The company leverages academic collaborations and in-house design of small molecules like simufilam. However, it faces significant competition from larger, better-resourced companies with established products and pipelines. Its reliance on third-party manufacturing and early-stage development status limit its competitive barriers.

• Drug Development Risk: The process of developing and obtaining regulatory approval for new drugs is lengthy, costly, and uncertain, with no guarantee of success.
• Manufacturing and Supply Chain Risk: Reliance on third-party manufacturers and suppliers exposes the company to risks of non-compliance with cGMP regulations, production delays, and supply interruptions.
• Competitive Risk: The company faces competition from larger pharmaceutical and biotechnology firms with greater financial resources and established market presence.
• Financial Risk: The company reported net losses and negative earnings per share, indicating ongoing funding needs and financial uncertainty.

• Cassava Sciences focuses on developing product candidates to diagnose and treat central nervous system (CNS) disorders, specifically TSC-related epilepsy.
• Their lead product candidate is simufilam, a small molecule designed to modulate the activity of filamin A, a scaffolding protein implicated in CNS diseases.
• Simufilam is considered a potential first-in-class filamin A modulating agent targeting TSC-related epilepsy.
• Preclinical studies in mouse models showed simufilam reduced seizure activity and neuronal abnormalities.
• The company discontinued development of SavaDx, an early-stage blood-based Alzheimer's disease detection program, as of mid-2025.
• Cassava Sciences outsources manufacturing and related activities, relying primarily on Evonik Corporation for clinical-grade simufilam supply.
• The company does not own or lease manufacturing facilities and depends on third-party vendors for formulation, manufacturing, packaging, and quality control.
• Simufilam and future candidates must comply with current good manufacturing practices (cGMP) and FDA regulations.
• The company faces competition from pharmaceutical and biotechnology companies, academic institutions, and others, with competitors often having greater resources and market presence.
• Two pharmacological treatment categories exist for TSC-related epilepsy: traditional anti-seizure medications and disease-specific ASMs, with two approved treatments (Afinitor Disperz and Epidiolex) currently available.
• Cassava Sciences reported research and development expenses of $26.6 million for the year ended December 31, 2025.
• From the SEC 10-Q filing for period ending March 31, 2026, the company had $86.6 million in cash and equivalents, $87.9 million in current assets, and $40.1 million in current liabilities, resulting in a current ratio of 2.19 and a cash ratio of 2.21, indicating liquidity.
• Net income for the quarter ending March 31, 2026, was a loss of $10.3 million, with basic EPS of -$0.21 per share.
• The company is subject to extensive FDA regulatory requirements for drug development, clinical trials, and manufacturing.
• Risk factors include the inherent risks of drug discovery and development, regulatory approval uncertainties, manufacturing compliance, and competitive pressures.